Product Name: Orlistat
Assay: 99%
CAS No.: 96829-58-2
Usages: Weight loss
Appearance: White fine powder

Also Name: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-(((2S, 3S)-3-HEXYL-4-OXO-2-OXETANYL)METHYL)-DODECYL ESTER; RO-18-0647; (-)-TETRAHYDROLIPSTATIN; N-FORMYL-L-LEUCINE (1S)-1-(((2S, 3S)-3-HEXYL-4-OXO-2-OXETANYL)METHYL)DODECYL ESTER; (-)-Tetrahydrolipstatin(EquivalentToOrlistat); Orlipastat; (1S)-1-{((2R, 3S)-3-hexyl-4-oxooxetan-2-yl)methyl}dodecyl N-formyl-D-leucinate; ((1S)-1-(((2S)-3-hexyl-4-oxo-oxetan-2-yl)methyl)dodecyl) (2S)-2-formamido-4-methyl-pentanoate


Descriptions
Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body mass. After orlistat was stopped, a significant number of subjects regained weight- Up to 35% of the weight they had lost.
The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).

Basic Data